The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 14, 2019

Filed:

Jul. 26, 2017
Applicant:

Cellectis, Paris, FR;

Inventors:

Roman Galetto, Paris, FR;

Agnes Gouble, Paris, FR;

Stephanie Grosse, Saint-cyr sur Morin, FR;

Cecile Mannioui, Villiers sur Marne, FR;

Laurent Poirot, Paris, FR;

Andrew Scharenberg, Seattle, WA (US);

Julianne Smith, Le Plessis-Robinson, FR;

Assignee:

CELLECTIS, Paris, FR;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/63 (2006.01); C12N 5/00 (2006.01); A61K 35/17 (2015.01); C12N 5/0783 (2010.01); C07K 14/725 (2006.01); C07K 16/28 (2006.01); C07K 14/705 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
A61K 35/17 (2013.01); C07K 14/7051 (2013.01); C07K 14/70517 (2013.01); C07K 14/70521 (2013.01); C07K 14/70578 (2013.01); C07K 16/28 (2013.01); C07K 16/2803 (2013.01); C12N 5/0636 (2013.01); A61K 38/00 (2013.01); C07K 2317/14 (2013.01); C07K 2317/24 (2013.01); C07K 2317/569 (2013.01); C07K 2317/622 (2013.01); C07K 2319/00 (2013.01); C07K 2319/03 (2013.01); C07K 2319/74 (2013.01); C12N 2501/39 (2013.01); C12N 2501/51 (2013.01); C12N 2501/515 (2013.01); C12N 2501/599 (2013.01); C12N 2502/99 (2013.01); C12N 2510/00 (2013.01);
Abstract

A method of expanding TCRalpha deficient T-cells by expressing pTalpha or functional variants thereof into said cells, thereby restoring a functional CD3 complex. This method is particularly useful to enhance the efficiency of immunotherapy using primary T-cells from donors. This method involves the use of pTalpha or functional variants thereof and polynucleotides encoding such polypeptides to expand TCRalpha deficient T-cells. Such engineered cells can be obtained by using specific rare-cutting endonuclease, preferably TALE-nucleases. The use of Chimeric Antigen Receptor (CAR), especially multi-chain CAR, in such engineered cells to target malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.


Find Patent Forward Citations

Loading…